COVID-19 大流行期间社区获得性肺炎的治疗。
Treatment of Community-Acquired Pneumonia During the Coronavirus Disease 2019 (COVID-19) Pandemic.
机构信息
Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (J.P.M.).
Royal Perth Hospital and University of Western Australia, Perth, Australia (G.W.W.).
出版信息
Ann Intern Med. 2020 Aug 18;173(4):304-305. doi: 10.7326/M20-2189. Epub 2020 May 7.
Abstract
Although pneumonia caused by severe acute respiratory syndrome coronavirus 2 is a prominent feature of COVID-19, clinicians must consider whether treatment for additional potential causes of community-acquired pneumonia (CAP) is appropriate. The cochairs of the recently released American Thoracic Society and Infectious Diseases Society of America Guideline for Treatment of Adults with CAP offer their interpretation of this guideline's application to the evaluation and treatment of patients with COVID-19.
摘要
虽然由严重急性呼吸综合征冠状病毒 2 引起的肺炎是 COVID-19 的一个显著特征，但临床医生必须考虑是否需要针对社区获得性肺炎 (CAP) 的其他潜在病因进行治疗。最近发布的美国胸科学会和传染病学会成人 CAP 治疗指南的共同主席对该指南在评估和治疗 COVID-19 患者中的应用提出了自己的解释。
相似文献
1
Treatment of Community-Acquired Pneumonia During the Coronavirus Disease 2019 (COVID-19) Pandemic.COVID-19 大流行期间社区获得性肺炎的治疗。
Ann Intern Med. 2020 Aug 18;173(4):304-305. doi: 10.7326/M20-2189. Epub 2020 May 7.
2
Community-acquired viral respiratory infections amongst hospitalized inpatients during a COVID-19 outbreak in Singapore: co-infection and clinical outcomes.新加坡 COVID-19 疫情期间住院患者的社区获得性病毒性呼吸道感染：合并感染和临床结局。
J Clin Virol. 2020 Jul;128:104436. doi: 10.1016/j.jcv.2020.104436. Epub 2020 May 19.
3
A single centre study of viral community-acquired pneumonia in children: No evidence of SARS-CoV-2 from October 2019 to March 2020.一项关于儿童社区获得性病毒性肺炎的单中心研究：2019 年 10 月至 2020 年 3 月期间无 SARS-CoV-2 证据。
J Clin Virol. 2020 Jul;128:104385. doi: 10.1016/j.jcv.2020.104385. Epub 2020 Apr 29.
4
Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting.COVID-19 住院患者的细菌和真菌感染：英国二级保健机构中的回顾性队列研究。
Clin Microbiol Infect. 2020 Oct;26(10):1395-1399. doi: 10.1016/j.cmi.2020.06.025. Epub 2020 Jun 27.
5
COVID-19: How to Prepare for the Pandemic?新型冠状病毒肺炎：如何为大流行做准备？
Indian J Pediatr. 2020 Jun;87(6):405-408. doi: 10.1007/s12098-020-03293-0. Epub 2020 Apr 13.
6
Practical tips for using masks in the COVID-19 pandemic.在新冠疫情期间使用口罩的实用小贴士。
Dermatol Ther. 2020 Jul;33(4):e13555. doi: 10.1111/dth.13555. Epub 2020 Jun 24.
7
Tuberculosis and novel Wuhan coronavirus infection: Pathological interrelationship.结核病与新型武汉冠状病毒感染：病理相互关系
Indian J Tuberc. 2020 Apr;67(2):264. doi: 10.1016/j.ijtb.2020.02.004. Epub 2020 Feb 26.
8
SARS-CoV-2 and HIV coinfection: clinical experience from Rhode Island, United States.SARS-CoV-2 和 HIV 合并感染：美国罗德岛的临床经验。
J Int AIDS Soc. 2020 Jul;23(7):e25573. doi: 10.1002/jia2.25573.
9
Clinical features and outcomes of adult COVID-19 patients co-infected with Mycoplasma pneumoniae.成人新冠病毒病患者合并肺炎支原体感染的临床特征及转归
J Infect. 2020 Sep;81(3):e12-e15. doi: 10.1016/j.jinf.2020.07.010. Epub 2020 Jul 8.
10
Recognition and management of respiratory co-infection and secondary bacterial pneumonia in patients with COVID-19.识别和管理 COVID-19 患者的呼吸道合并感染和继发性细菌性肺炎。
Cleve Clin J Med. 2020 Nov 2;87(11):659-663. doi: 10.3949/ccjm.87a.ccc015.
引用本文的文献
1
Optimizing Antimicrobial Use in Japan: Strategies for Dosage, Combination Therapy, De-Escalation, Oral Switching, Duration, and Guideline Adherence.优化日本抗菌药物的使用：剂量、联合治疗、降阶梯治疗、口服转换、疗程及指南依从性策略
Clin Pharmacol. 2025 Aug 4;17:227-233. doi: 10.2147/CPAA.S539674. eCollection 2025.
2
Integrating bioinformatics and machine learning to investigate the mechanisms by which three major respiratory infectious diseases exacerbate heart failure.整合生物信息学和机器学习以研究三种主要呼吸道传染病加重心力衰竭的机制。
Sci Rep. 2025 Jul 2;15(1):23526. doi: 10.1038/s41598-025-07090-7.
3
Antibiotic Treatment in Patients Hospitalized for Nonsevere COVID-19.非重症新冠病毒肺炎住院患者的抗生素治疗
JAMA Netw Open. 2025 May 1;8(5):e2511499. doi: 10.1001/jamanetworkopen.2025.11499.
4
Clinical Differences Between Survivors and Non-Survivors of Ventilator-Associated Pneumonia: The Roles of Sulbactam/Ampicillin and Methicillin-Resistant .呼吸机相关性肺炎幸存者与非幸存者的临床差异：舒巴坦/氨苄西林和耐甲氧西林的作用
Infect Drug Resist. 2024 Dec 27;17:5875-5879. doi: 10.2147/IDR.S497536. eCollection 2024.
5
Evaluation of Soluble Urokinase Plasminogen Activator Receptor in COVID-19 Patients.新冠病毒肺炎患者可溶性尿激酶型纤溶酶原激活物受体的评估
J Clin Med. 2024 Oct 23;13(21):6340. doi: 10.3390/jcm13216340.
6
Repositioning of Antibiotics in the Treatment of Viral Infections.抗生素在病毒感染治疗中的再定位。
Curr Microbiol. 2024 Oct 26;81(12):427. doi: 10.1007/s00284-024-03948-7.
7
Changes in respiratory infection trends during the COVID-19 pandemic in patients with haematologic malignancy.COVID-19 大流行期间血液恶性肿瘤患者呼吸道感染趋势的变化。
BMC Pulm Med. 2024 May 26;24(1):259. doi: 10.1186/s12890-024-03071-0.
8
Bacterial Community- and Hospital-Acquired Pneumonia in Patients with Critical COVID-19-A Prospective Monocentric Cohort Study.重症新型冠状病毒肺炎患者的细菌群落与医院获得性肺炎——一项前瞻性单中心队列研究
Antibiotics (Basel). 2024 Feb 16;13(2):192. doi: 10.3390/antibiotics13020192.
9
Early empiric antibiotic use in COVID-19 patients: results from the international VIRUS registry.COVID-19 患者早期经验性使用抗生素：来自国际 VIRUS 登记处的结果。
Int J Infect Dis. 2024 Mar;140:39-48. doi: 10.1016/j.ijid.2023.12.006. Epub 2023 Dec 19.
10
[Bacterial coinfection in the critically-ill COVID-19 patient: incidence, impact and need for antimicrobial therapy].[危重症 COVID-19 患者的细菌合并感染：发生率、影响及抗菌治疗需求]
Rev Esp Quimioter. 2023 Dec;36(6):612-620. doi: 10.37201/req/060.2023. Epub 2023 Sep 25.
本文引用的文献
1
Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study.85 例武汉 COVID-19 死亡病例的临床特征。一项回顾性观察研究。
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1372-1379. doi: 10.1164/rccm.202003-0543OC.
2
Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review.新型冠状病毒病 2019（COVID-19）的胸部 CT 表现：影像学综述。
Eur Radiol. 2020 Aug;30(8):4381-4389. doi: 10.1007/s00330-020-06801-0. Epub 2020 Mar 19.
3
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
4
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
5
Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.成人社区获得性肺炎诊断和治疗。美国胸科学会和美国传染病学会的官方临床实践指南。
Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67. doi: 10.1164/rccm.201908-1581ST.
6
Effectiveness of a Bundled Intervention Including Adjunctive Corticosteroids on Outcomes of Hospitalized Patients With Community-Acquired Pneumonia: A Stepped-Wedge Randomized Clinical Trial.包括辅助性皮质类固醇在内的综合干预措施对社区获得性肺炎住院患者结局的有效性：一项阶梯式楔形随机临床试验
JAMA Intern Med. 2019 Aug 1;179(8):1052-1060. doi: 10.1001/jamainternmed.2019.1438.
7
Procalcitonin as a Marker of Etiology in Adults Hospitalized With Community-Acquired Pneumonia.降钙素原作为成人社区获得性肺炎病因标志物的研究。
Clin Infect Dis. 2017 Jul 15;65(2):183-190. doi: 10.1093/cid/cix317.
8
Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.美国成年人中需要住院治疗的社区获得性肺炎
N Engl J Med. 2015 Jul 30;373(5):415-27. doi: 10.1056/NEJMoa1500245. Epub 2015 Jul 14.
9
Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial.降钙素原指导社区获得性肺炎抗生素治疗的随机试验
Am J Respir Crit Care Med. 2006 Jul 1;174(1):84-93. doi: 10.1164/rccm.200512-1922OC. Epub 2006 Apr 7.
10
Limited value of routine microbiological diagnostics in patients hospitalized for community-acquired pneumonia.社区获得性肺炎住院患者常规微生物诊断的价值有限。
Scand J Infect Dis. 2002;34(12):873-9. doi: 10.1080/0036554021000026967.
Zotero 插件